CPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Catalyst Pharmaceuticals Inc (CPRX) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While the stock has a positive analyst rating and a raised price target, the recent financial performance shows declining net income, EPS, and gross margin. Technical indicators are neutral, and there are no significant trading signals or news catalysts to support an immediate buy decision. The investor may consider monitoring the stock for better entry points or positive developments.
The MACD histogram is negative (-0.0328) and contracting, indicating a lack of upward momentum. RSI is neutral at 51.736, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level (23.878), with resistance at 24.974 and support at 22.781.
Analyst Samantha Semenkow raised the price target to $35 from $33 and maintained a Buy rating. The stock has a 3.52% chance of increasing in the next month based on historical patterns.
Financial performance in Q4 2025 showed a decline in net income (-5.79% YoY), EPS (-6.82% YoY), and gross margin (-1.84% YoY). No significant news or trading trends have been observed recently. Post-market price change is negative (-0.95%), and the stock is underperforming relative to the S&P 500 (-0.56%).
In Q4 2025, revenue increased by 7.61% YoY to $152.6M. However, net income dropped to $52.7M (-5.79% YoY), EPS decreased to 0.41 (-6.82% YoY), and gross margin fell to 76.71% (-1.84% YoY).
Citi analyst Samantha Semenkow raised the price target to $35 from $33 and maintained a Buy rating. The update followed the Q4 financial report.
